List AF - Search Results

1

Identification of a novel inhibitor of JAK2 tyrosine kinase by structure-based virtual screening.

Kiss R, Polgár T, Kirabo A, Sayyah J, Figueroa NC, List AF, Sokol L, Zuckerman KS, Gali M, Bisht KS, Sayeski PP, Keseru GM. Kiss R, et al. Among authors: list af. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3598-601. doi: 10.1016/j.bmcl.2009.04.138. Epub 2009 May 5. Bioorg Med Chem Lett. 2009. PMID: 19447617 Free PMC article.

2

Immunomodulatory therapy for myelodysplastic syndromes.

Sokol L, List AF. Sokol L, et al. Among authors: list af. Int J Hematol. 2007 Nov;86(4):301-5. doi: 10.1532/IJH97.06063. Int J Hematol. 2007. PMID: 18055335

3

Developmental therapeutics for myelodysplastic syndromes.

Naing A, Sokol L, List AF. Naing A, et al. Among authors: list af. J Natl Compr Canc Netw. 2006 Jan;4(1):78-82. doi: 10.6004/jnccn.2006.0008. J Natl Compr Canc Netw. 2006. PMID: 16403406 Review.

4

Erythropoietin receptor signaling is membrane raft dependent.

McGraw KL, Fuhler GM, Johnson JO, Clark JA, Caceres GC, Sokol L, List AF. McGraw KL, et al. Among authors: list af. PLoS One. 2012;7(4):e34477. doi: 10.1371/journal.pone.0034477. Epub 2012 Apr 3. PLoS One. 2012. PMID: 22509308 Free PMC article.

5

Lenalidomide induces lipid raft assembly to enhance erythropoietin receptor signaling in myelodysplastic syndrome progenitors.

McGraw KL, Basiorka AA, Johnson JO, Clark J, Caceres G, Padron E, Heaton R, Ozawa Y, Wei S, Sokol L, List AF. McGraw KL, et al. Among authors: list af. PLoS One. 2014 Dec 3;9(12):e114249. doi: 10.1371/journal.pone.0114249. eCollection 2014. PLoS One. 2014. PMID: 25469886 Free PMC article.

6

T-cell large granular lymphocyte proliferation in myelodysplastic syndromes: Clinicopathological features and prognostic significance.

Zhang X, Sokol L, Bennett JM, Moscinski LC, List A, Zhang L. Zhang X, et al. Leuk Res. 2016 Apr;43:18-23. doi: 10.1016/j.leukres.2016.02.006. Epub 2016 Feb 17. Leuk Res. 2016. PMID: 26927701

7

Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.

Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A. Zhou L, et al. Cancer Res. 2011 Feb 1;71(3):955-63. doi: 10.1158/0008-5472.CAN-10-2933. Epub 2010 Dec 28. Cancer Res. 2011. PMID: 21189329 Free PMC article.

8

Between a rux and a hard place: evaluating salvage treatment and outcomes in myelofibrosis after ruxolitinib discontinuation.

Kuykendall AT, Shah S, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Kuykendall AT, et al. Among authors: list af. Ann Hematol. 2018 Mar;97(3):435-441. doi: 10.1007/s00277-017-3194-4. Epub 2017 Nov 30. Ann Hematol. 2018. PMID: 29189896

9

HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1.

Caceres G, Robey RW, Sokol L, McGraw KL, Clark J, Lawrence NJ, Sebti SM, Wiese M, List AF. Caceres G, et al. Among authors: list af. Cancer Res. 2012 Aug 15;72(16):4204-13. doi: 10.1158/0008-5472.CAN-12-0743. Epub 2012 Jul 3. Cancer Res. 2012. PMID: 22761337 Free PMC article.

10

The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.

Kuykendall AT, Talati C, Al Ali N, Sweet K, Padron E, Sallman DA, Lancet JE, List AF, Zuckerman KS, Komrokji RS. Kuykendall AT, et al. Among authors: list af. Clin Lymphoma Myeloma Leuk. 2017 Dec;17(12):e45-e53. doi: 10.1016/j.clml.2017.08.002. Epub 2017 Aug 5. Clin Lymphoma Myeloma Leuk. 2017. PMID: 28869184

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

323 results

Search Page